DrugPatentWatch Database Preview
Lannett Co Inc Company Profile
What is the competitive landscape for LANNETT CO INC, and when can generic versions of LANNETT CO INC drugs launch?
LANNETT CO INC has one hundred and thirty-one approved drugs.
There is one US patent protecting LANNETT CO INC drugs.
Summary for Lannett Co Inc
| US Patents: | 1 |
| Tradenames: | 102 |
| Ingredients: | 94 |
| NDAs: | 131 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for Lannett Co Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-003 | May 27, 2003 | AB2 | RX | Yes | No | 6,344,215 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Lannett Co Inc | TEMOZOLOMIDE | temozolomide | CAPSULE;ORAL | 203898-005 | Feb 10, 2016 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | LOPINAVIR AND RITONAVIR | lopinavir; ritonavir | SOLUTION;ORAL | 207407-001 | Dec 27, 2016 | AA | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | NIACIN | niacin | TABLET, EXTENDED RELEASE;ORAL | 203899-002 | Jun 16, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-002 | Jun 19, 2003 | AB2 | RX | Yes | No | 6,344,215 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Lannett Co Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lannett Co Inc | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT CO INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-03-15 |
| ➤ Subscribe | Extended-release Capsules | 10 mg, 20 mg and 30 mg | ➤ Subscribe | 2005-05-13 |
International Patents for Lannett Co Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2426883 | ➤ Sign Up |
| Poland | 203828 | ➤ Sign Up |
| European Patent Office | 2286815 | ➤ Sign Up |
| European Patent Office | 2269605 | ➤ Sign Up |
| European Patent Office | 1328251 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Lannett Co Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB01/006 | United Kingdom | ➤ Sign Up | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
| C0020 | France | ➤ Sign Up | PRODUCT NAME: COMBINAISON COMRENANT L’ALISKIREN SOUS FORME DE BAE LIBRE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, ET L’HYDROCHLOROTHIAZIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/08/491/001 DU 20090116; REGISTRATION NO/DATE AT EEC: 58935 01-04 DU 20081028 |
| /1999 | Austria | ➤ Sign Up | PRODUCT NAME: MONTELUKAST ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE MONTELUKASTNATRIUM; NAT. REGISTRATION NO/DATE: 1-22765 UND 1-22766 19981030; FIRST REGISTRATION: FI 12766 UND 12767 19970825 |
| C0032 | Belgium | ➤ Sign Up | PRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506 |
| 00085 | Netherlands | ➤ Sign Up | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
